TLCD3A and prostate carcinoma: These latter findings, however, were challenged by a study which correlated increased FAM57A transcript levels with unfavorable clinical parameters in prostate cancer patients and reported anti-proliferative effects of FAM57A silencing in 22Rv1 prostate cancer cells [17].